Mesenchymal Stromal Cells in Chronic EAE Models
Mesenchymal stromal cells (MSCs) were shown to reduce disease severity and inflammation in chronic EAE models, and to enhance neuroprotection. Their effectiveness improved when administered intrathecally or intraventricularly.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Not graded
- Outcome
- Not reported
Why it matters
These findings suggest that MSCs have immunomodulatory and neuroprotective effects, which could be significant for treating progressive multiple sclerosis (PMS). However, the relevance to clinical outcomes in humans remains unclear due to variability in early trials.
What this does not prove
Early-phase clinical trials in PMS indicate favorable safety but mixed efficacy, likely due to differences in study design, cell products, and administration methods.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-06-12
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- neurotrophic factors, angiogenic factors
- Pathway
- Not reported
- Population
- Progressive multiple sclerosis patients
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceMesenchymal stromal cells for progressive multiple sclerosis: current evidence and translational challenges. ↗DOI: 10.1016/j.jcyt.2026.102935
Supporting passages (7)
publication date2026-06-12
interventionMesenchymal stromal cells
findingsIn chronic EAE models, MSC consistently reduce disease severity, mitigate CNS inflammation, and promote neuroprotection, with enhanced efficacy following intrathecal or intraventricular administration.
limitationsEarly-phase clinical trials in PMS have demonstrated a favorable safety profile but inconsistent efficacy, likely reflecting substantial heterogeneity in study design, cell products, dosing regimens, and administration routes.
biological targetsBeyond immune regulation, MSC promote CNS repair by secreting neurotrophic and angiogenic factors and through mitochondrial transfer.
populationTitle: Mesenchymal stromal cells for progressive multiple sclerosis: current evidence and translational challenges.
peer reviewedPublication types: Journal Article; Review
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.